Follow
Vincent Marconi
Vincent Marconi
Professor of Medicine, Emory University
Verified email at emory.edu
Title
Cited by
Cited by
Year
Code saturation versus meaning saturation: how many interviews are enough?
MM Hennink, BN Kaiser, VC Marconi
Qualitative health research 27 (4), 591-608, 2017
35522017
Baricitinib plus remdesivir for hospitalized adults with Covid-19
AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ...
New England Journal of Medicine 384 (9), 795-807, 2021
17412021
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
International HIV Controllers Study
Science 330 (6010), 1551-1557, 2010
11072010
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 …
VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ...
The lancet Respiratory medicine 9 (12), 1407-1418, 2021
6542021
Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study
JF Okulicz, VC Marconi, ML Landrum, S Wegner, A Weintrob, A Ganesan, ...
The Journal of infectious diseases 200 (11), 1714-1723, 2009
3682009
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study
N Crum-Cianflone, KH Hullsiek, V Marconi, A Weintrob, A Ganesan, ...
Aids 23 (1), 41-50, 2009
3432009
HIV treatment adherence, drug resistance, virologic failure: evolving concepts
JB Nachega, VC Marconi, GU Van Zyl, EM Gardner, W Preiser, SY Hong, ...
Infectious disorders drug targets 11 (2), 167, 2011
3022011
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa
VC Marconi, H Sunpath, Z Lu, M Gordon, K Koranteng-Apeagyei, ...
Clinical infectious diseases 46 (10), 1589-1597, 2008
3012008
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ...
The Lancet infectious diseases 16 (5), 565-575, 2016
2772016
Increasing rates of obesity among HIV-infected persons during the HIV epidemic
N Crum-Cianflone, MP Roediger, L Eberly, M Headd, V Marconi, ...
Plos one 5 (4), e10106, 2010
2682010
Anal cancers among HIV-infected persons: HAART is not slowing rising incidence
NF Crum-Cianflone, KH Hullsiek, VC Marconi, A Ganesan, A Weintrob, ...
Aids 24 (4), 535-543, 2010
2342010
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE ε4/ε4 genotype accelerates HIV disease progression
TD Burt, BK Agan, VC Marconi, W He, H Kulkarni, JE Mold, M Cavrois, ...
Proceedings of the National Academy of Sciences 105 (25), 8718-8723, 2008
2332008
The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States
CS Kraft, AL Hewlett, S Koepsell, AM Winkler, CJ Kratochvil, LA Larson, ...
Clinical infectious diseases 61 (4), 496-502, 2015
2232015
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility
W He, S Neil, H Kulkarni, E Wright, BK Agan, VC Marconi, MJ Dolan, ...
Cell host & microbe 4 (1), 52-62, 2008
2232008
Development of a definition of postacute sequelae of SARS-CoV-2 infection
T Thaweethai, SE Jolley, EW Karlson, EB Levitan, B Levy, GA McComsey, ...
Jama 329 (22), 1934-1946, 2023
2102023
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms
MJ Dolan, H Kulkarni, JF Camargo, W He, A Smith, JM Anaya, T Miura, ...
Nature immunology 8 (12), 1324-1336, 2007
2072007
Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care
PG Farnham, C Gopalappa, SL Sansom, AB Hutchinson, JT Brooks, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 64 (2), 183-189, 2013
1712013
CTLA-4+ PD-1− memory CD4+ T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques
CS McGary, C Deleage, J Harper, L Micci, SP Ribeiro, S Paganini, ...
Immunity 47 (4), 776-788. e5, 2017
1632017
Use of baricitinib in patients with moderate to severe coronavirus disease 2019
BK Titanji, MM Farley, A Mehta, R Connor-Schuler, A Moanna, SK Cribbs, ...
Clinical Infectious Diseases 72 (7), 1247-1250, 2021
1592021
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ...
The Lancet Respiratory Medicine 10 (4), 327-336, 2022
1582022
The system can't perform the operation now. Try again later.
Articles 1–20